BackgroundCOPD is a treatable disease with increasing prevalence worldwide. Treatment aims to stop disease progression, to improve quality of life, and to reduce exacerbations. We aimed to evaluate the association of the stage of COPD on adherence to inhaled therapy and the relationship between adherence and COPD exacerbations.MethodsA retrospective analysis of patients hospitalized for acute exacerbation of COPD in a tertiary care hospital in Upper Austria and discharged with a guideline conform inhaled therapy was performed. Follow-up data on medical utilization was recorded for the subsequent 24months. Adherence to inhaled therapy was defined according to the percentage of prescribed inhalers dispensed to the patient and classified as complete (>80%), partial (50-80%) or low (<50%).ResultsOut of 357 patients, 65.8% were male with a mean age of 66.5years and a mean FEV1 of 55.0%pred. Overall, 35.3% were current smokers, and only 3.9% were never-smokers. In 77.0% inhaled triple therapy (LAMA + LABA + ICS) was prescribed. 33.6% showed complete adherence to their therapy (33.2% in men, 34.4% in women), with a mean age of 67.0years. Mean medication possession ratio by GOLD spirometry class I - IV were 0.486, 0.534, 0.609 and 0.755, respectively (p=0.002). Hence, subjects with complete adherence to therapy had a significantly lower FEV1 compared to those with low adherence (49.2%pred. vs 59.2%pred., respectively; p<0.001).The risk of exacerbations leading to hospitalization was 10-fold higher in GOLD spirometry class IV compared to GOLD spirometry class I, which was even more evident in multivariate analysis (OR 13.62).ConclusionComplete adherence to inhaled therapy was only seen in 33.6% and was higher among those with more severe COPD.Trial registrationNot applicable.
机构:
GSK, R&D Global Med, Value Evidence & Outcomes, Brentford, Middlesex, EnglandGSK, R&D Global Med, Value Evidence & Outcomes, Brentford, Middlesex, England
Requena, G.
Rothnie, K.
论文数: 0引用数: 0
h-index: 0
机构:
GSK, R&D Global Med, Value Evidence & Outcomes, Brentford, Middlesex, EnglandGSK, R&D Global Med, Value Evidence & Outcomes, Brentford, Middlesex, England
Rothnie, K.
Noorduyn, S. G.
论文数: 0引用数: 0
h-index: 0
机构:
GSK, Value Evidence & Outcomes, Mississauga, ON, CanadaGSK, R&D Global Med, Value Evidence & Outcomes, Brentford, Middlesex, England
Noorduyn, S. G.
Claussen, J.
论文数: 0引用数: 0
h-index: 0
机构:
GSK, Global Med Affairs, Munich, GermanyGSK, R&D Global Med, Value Evidence & Outcomes, Brentford, Middlesex, England
Claussen, J.
Schultze, M.
论文数: 0引用数: 0
h-index: 0
机构:
ZEG Berlin Ctr Epidemiol & Hlth Res GmbH, Berlin, GermanyGSK, R&D Global Med, Value Evidence & Outcomes, Brentford, Middlesex, England
Schultze, M.
Kossack, N.
论文数: 0引用数: 0
h-index: 0
机构:
WIG2 GmbH, Wissenschaftliches Inst Gesundheitsokonomie & Ges, Sci Inst Hlth Econ & Hlth Syst Res, Leipzig, Sachsen, GermanyGSK, R&D Global Med, Value Evidence & Outcomes, Brentford, Middlesex, England
Kossack, N.
Richter, L.
论文数: 0引用数: 0
h-index: 0
机构:
WIG2 GmbH, Wissenschaftliches Inst Gesundheitsokonomie & Ges, Sci Inst Hlth Econ & Hlth Syst Res, Leipzig, Sachsen, GermanyGSK, R&D Global Med, Value Evidence & Outcomes, Brentford, Middlesex, England
Richter, L.
Vogelmeier, C.
论文数: 0引用数: 0
h-index: 0
机构:
Philipps Univ Marburg, Univ Med Ctr Giessen & Marburg, German Ctr Lung Res DZL, Dept Med Pulm & Crit Care Med, Marburg, GermanyGSK, R&D Global Med, Value Evidence & Outcomes, Brentford, Middlesex, England
Vogelmeier, C.
Beeh, K. M.
论文数: 0引用数: 0
h-index: 0
机构:
Insaf Resp Res Inst, Wiesbaden, GermanyGSK, R&D Global Med, Value Evidence & Outcomes, Brentford, Middlesex, England
Beeh, K. M.
Sharma, R.
论文数: 0引用数: 0
h-index: 0
机构:
GSK, Global Med, Brentford, Middlesex, EnglandGSK, R&D Global Med, Value Evidence & Outcomes, Brentford, Middlesex, England
Sharma, R.
Compton, C.
论文数: 0引用数: 0
h-index: 0
机构:
GSK, Global Med, Brentford, Middlesex, EnglandGSK, R&D Global Med, Value Evidence & Outcomes, Brentford, Middlesex, England
Compton, C.
Ismaila, A.
论文数: 0引用数: 0
h-index: 0
机构:
GSK, R&D Global Med, Value Evidence & Outcomes, Collegeville, PA USAGSK, R&D Global Med, Value Evidence & Outcomes, Brentford, Middlesex, England